• Users Online: 275
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 


 
 Table of Contents  
CASE REPORT
Year : 2020  |  Volume : 12  |  Issue : 1  |  Page : 44-48

A rare encounter in nonsuspecting circumstances: First congenital visceral leishmaniasis (kala-azar) in Libya


1 Department of Pediatric Gastroenterology and Hepatology, Tripoli University Hospital, Tripoli, Libya
2 Department of Pediatric Gastroenterology and Hepatology, Tripoli University Hospital; Department of Pediatric, Faculty of Medicine, University of Tripoli, Tripoli, Libya
3 National Centre for Disease Control, Tripoli, Libya

Date of Submission01-Feb-2020
Date of Decision01-Feb-2020
Date of Acceptance01-Feb-2020
Date of Web Publication26-Mar-2020

Correspondence Address:
Fauzi Abdalla Sagher
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Tripoli University Hospital, Tripoli; Department of Pediatric, Faculty of Medicine, University of Tripoli, Tripoli
Libya
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmbs.ijmbs_9_20

Rights and Permissions
  Abstract 


Congenital transmission of Leishmaniasis is very rare. It occurs through blood exchange from the mother to the child during pregnancy or delivery. We report the first confirmed congenital leishmaniasis in a 4-month-old Libyan boy with prolonged jaundice and hepatosplenomegaly. This was a congenital transmission from his mother who was asymptomatic and not known to have leishmaniasis, which was confirmed after the diagnosis of the infant. Despite treatment, the infant died. The diagnostic approach is illustrated by the case report. Poor obstetric history in the mother may be related to her own undiagnosed kala azar.

Keywords: Congenital kala azar, Leishmania infantum, visceral leishmaniasis


How to cite this article:
Elarabi AS, Saad ZA, Saadawi WK, Aldobea NM, Sagher FA. A rare encounter in nonsuspecting circumstances: First congenital visceral leishmaniasis (kala-azar) in Libya. Ibnosina J Med Biomed Sci 2020;12:44-8

How to cite this URL:
Elarabi AS, Saad ZA, Saadawi WK, Aldobea NM, Sagher FA. A rare encounter in nonsuspecting circumstances: First congenital visceral leishmaniasis (kala-azar) in Libya. Ibnosina J Med Biomed Sci [serial online] 2020 [cited 2020 Apr 2];12:44-8. Available from: http://www.ijmbs.org/text.asp?2020/12/1/44/281407




  Introduction Top


Leishmaniasis, a vector-borne disease, is transmitted to humans through the bite of phlebotomine sand flies. Leishmania donovani, a protozoan parasite, is the primary causative agent for visceral leishmaniasis (VL). The incubation period after vector transmission is highly variable, typically 2–6 months, yet it may widely vary from 10 days to longer than 10 years. The classical manifestations of VL are persistent fever, weight loss, progressive anemia or pancytopenia, hepatosplenomegaly, and hypergammaglobulinaemia.[1] Recognized risk factors for leishmaniasis include low socioeconomic status, malnutrition, and poor housing, and there is some evidence of genetic predisposition.[1]

VL is estimated to affect about 200,000–400,000 cases/year. Majority (>90%) of people who develop VL live in poor rural regions of Bangladesh, Ethiopia, India, Nepal, Sudan, and Brazil.[1] Nonvector transmission occurs occasionally through blood transfusions, contaminated needles of drug users, organ transplants, or laboratory infection.

Congenital transmission may occur either through blood exchange from the mother to the child during delivery or by transplacental infection during pregnancy.[1] We report the first Libyan case of congenital transmission of VL from an asymptomatic mother representing a rare encounter in nonsuspecting circumstances.


  Case Report Top


Case history

A 4-month-old Libyan male infant referred to pediatric gastroenterology and hepatology clinic in Tripoli University Hospital for prolonged jaundice and hepatosplenomegaly. He is a product of nonconsanguineous parents born by uneventful vaginal at term with a birth weight of 2 kg. He received the birth dose of vaccination and was fed by a mixture of breast and bottle feeding. His yellowish discoloration of skin and sclera was noticed by the parents at the age of 45 days, followed by abdominal distension not associated with fever or weight loss. The mother has three healthy children. However, 3 years previously, she lost one boy who died at the age of 3 months with a similar complaint. Furthermore, she had a twin intrauterine fetal death at 6 months of gestation immediately before the index case. The family lives in Ubari, a town in the far southwestern part of Libya. They live in an impoverished socioeconomic state, with a history of traditional remedies, and they reported no history of distant travel.

Physical examination

PO examination, the baby looked pale and icteric, with palmer erythema, and had generalized lymph-adenopathy and mouth thrash. No specific dysmorphic features were noted. His weight was 4.25 kg (i.e., <3rd centile), length was 58 cm (on the 3rd centile), and occipitofrontal head circumference was 37 cm (<3rd centile). Cardiorespiratory and central nervous systems were normal. The abdomen was distended, with visibly dilated veins and palpable liver (right lobe 9 cm and left lobe 4 cm below the costal margin). The liver was firm in consistency with sharp edge. The spleen was massively enlarged down to the left iliac fossa. No ascites was evident. He had a normal external male genitalia with severe napkin rash.

Investigations

Hematological and biochemical investigations revealed leukocytosis with neutrophilia and cholestasis, conjugated hyperbilirubinemia, and hepatocellular damage [Table 1]. Abdominal ultrasound scan showed hepatosplenomegaly obliterated fibrotic biliary radicals with bilateral medullary sponge kidneys and no ascites. Bone marrow aspiration was reported normal with no evidence of blast cells, or L. donovani antibodies, or histiocytes, or lipid foamy cells. Bone marrow biopsy revealed erythroid hyperplasia along with intermingling macrophages showing vacuolated and granular dots like, making the possibility of leishmaniasis high on the list [Figure 1]. DNA was extracted from the bone marrow using QIAamp Tissue Kit (Qiagen, Hilden, Germany) and screened for internal transcribed spacer 1 region of the rRNA genes in Leishmania spp. by polymerase chain reaction (PCR) using the primer pair LITSR (5-CTG GAT CAT TTT CCG ATG-3) and L5.8S (5-TGA TAC CAC TTA TCG CAC TT-3). The PCR products were visualized using ultraviolet transillumination with GelRed dye (GIBCO BRL Life Technologies, Inc., Gaithersburg, MD, USA) on 1.55 agarose gel (SIGMA, St. Louis) in 1X TAE buffer for 45 min at 100 V after electrophoresis; the size of the amplified product was determined by comparison with a 100 bp ladder (Sigma-Aldrich, USA).[2] The results were positive for Leishmania infantum [Figure 2].
Table 1: Laboratory investigations of the patient

Click here to view
Figure 1: Bone marrow biopsy showing erythroid hyperplasia along with intermingling macrophages, vacuolated and granular dots like, making the possibility of leishmaniasis high on the list

Click here to view
Figure 2: Gel images of representative polymerase chain reaction amplification of Leishmania DNA. Amplifications of the internal transcribed spacer 1 gene shown in lanes 3, M is 100 bp molecular marker, lane 1 is negative control, and lane 2 is a positive control

Click here to view


Assessment of the mother

The mother is a 24-year-old native Libyan. She was healthy with no specific complaint or previous hospital admissions. Basic investigations including complete blood count, kidney and liver function tests, and abdominal ultrasound scan were all normal. Further investigations by serological test for L. infantum (ELISA IgG, DRG Diagnostics, Marburg-Germany) were positive, and her peripheral blood film showed a full field of Leishmania amastigote as shown in [Figure 3].
Figure 3: Peripheral blood film of the mother stained with Giemsa stain showing Leishmania amastigotes

Click here to view


Management and outcome

For the infant, antibiotic therapy (ceftriaxone) plus supportive therapy (fresh frozen plasma and fat-soluble vitamins) was started with no clinical improvement. Later, specific therapy with pentavalent antimonial sodium stibogluconate (pentostam) 20 mg/kg body weight was given immediately after bone marrow biopsy was taken. Unfortunately, the patient died after finishing the seventh dose of therapy. The mother received pentavalent antimonial therapy with sodium stibogluconate (pentostam) for 1 month. The mother was lost for follow-up after starting the therapy.


  Discussion Top


Kala azar was first described in Greece in 1835 and several decades later in India 1882.[3] In Libya, VL is due to L. infantum. It occurs in two endemic areas, in the northeastern region precisely Al Jabel Al Akhdar, and in the southern region in Ubari where our infant and mother come from. Domestic dogs (Canis familiaris) are the primary reservoir hosts in the Mediterranean Basin. The Libya National Center for Disease Control (NCDC) reported five deaths out of 31 confirmed cases between 2013 and 2017.[4],[5]

Although most of the congenital VL (CVL) observed after the mother had symptomatic VL during pregnancy, two reported cases in Germany were congenitally infected from asymptomatic mothers. The first case was a 16-month-old boy reported by Meinecke et al.[6] and the other one was a 9-month-old German girl who had never been to a VL-endemic area as reported by Boehme et al.[7] In both cases, the mothers had never been symptomatic for VL, but laboratory investigations confirmed the infection. The present case is the first reported case of CVL in Libya and third reported case of congenitally transmitted visceral Leishmania from an asymptomatic mother in the world, as she was a young, healthy female and had never been symptomatic for Leishmania infection. She had no history of traveling outside Libya. However, she lives in an endemic area for VL, had a history of twin intrauterine fetal death at 6-month gestation before this pregnancy, in addition to the history of her son who presented with a similar history but died 3 years ago, all suggesting the congenital route of infection.

The diagnosis of Leishmania should be confirmed by either the microscopic identification of the amastigote or promastigote forms of the parasite in liver, spleen, or bone marrow biopsies or by the detection of the desoxyribonucleic acid of Leishmania in blood or biopsy material using PCR.[7] In the present case, the diagnosis was undoubtedly confirmed by bone marrow PCR for the infant and direct visualization of amastigote in peripheral blood film of the mother.

The main drugs available for the treatment of VL are the systemic agents such as pentavalent antimonials (sodium stibogluconate [SSG] and meglumine antimoniate, amphotericin B, and liposomal amphotericin B (L-AmB), and the oral drug miltefosine.[8] Liposomal amphotericin B (LAB) has better tissue penetration effect and is more effective at lower doses, reducing toxicities.[8] Hence, it is strongly recommended as the first-choice drug in pregnancy due to its fewer materno–fetal adverse effects.[9] There are no incidents of vertical transmission of the disease or any repercussion on the fetus reported following the use of L-AmB. Successful results for both mother and fetus with liposomal amphotericin-B were reported in 2017 byPPeriklis in Greece,[10] in a symptomatic mother treated for VL 2 months before delivery. A single dose of liposomal amphotericin B (L-AmB) and multidrug therapy (L-AmB + miltefosine, L-AmB + paromomycin (PM), or miltefosine + PM) is the treatment of choice for VL in the Indian subcontinent. The combination of SSG with PM for 17 days is used as the treatment of choice in East Africa and Yemen, whereas L-AmBup at a total dose of 18–21 mg/kg remains the choice in Mediterranean Basin, Middle East, and Central Asia. Recently, miltefosine (hexadecylphosphocholine) is effective orally against kala azar. All clinical trials with this drug were conducted in India in VL patients. A regimen of 100 mg per day or 50 mg twice daily for 3–4 weeks was reported to achieve a cure rate of 100%. Gastrointestinal side effects were frequent (62%), but no patient discontinued the therapy.[11]


  Conclusions Top


The diagnosis of VL should be considered in children with fever and splenomegaly with or without pancytopenia. This should be the case despite the lack of the child's travel to an endemic area and lack of absence of evidence of the disease in the immediate environment. Albeit rare, leishmaniasis can be transmitted congenitally from an asymptomatic mother to her child. Late diagnosis as reported here is associated with poor outcome. Bad obstetric history of the mother could be related to her undiagnosed kala azar.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for the history and radiological and pathological images and other clinical information to be reported in the journal. She understands that name and initial will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Acknowledgment

The authors would like to express their cordial thanks and gratitude to Dr. Ahmed Elgrari, Director of Zoonotic Disease Control Administrative at NCDC, and to Professor Bader Eddin B Annajar, Director General, NCDC, and all the staff of the Reference Laboratory of Parasitology and Vector borne Disease for their help in the management of this case.

Authors' contributions

All authors contributed to the assessment, investigations, and/or provision of the ancillary investigations. All authors were involved in the drafting, revision, and approval of the final version.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Compliance with ethical principles

No prior formal ethical approval is required for individual case reports or anonymized small series. However, a consent was obtained from the mother for reporting of her case anonymously.



 
  References Top

1.
Karimi A, Alborzi A, Amanati A. Visceral leishmaniasis: An update and literature review. Arch Pediatr Infect Dis 2016;4:e31612.  Back to cited text no. 1
    
2.
Dabirzadeh M, Hashemi M, Maroufi Y. Study of genetic variation of leishmania major based on internal transcribe spacer 1 (ITS1) in Chabahar, Iran. Jundishapur J Microbiol 2016;9:e33498.  Back to cited text no. 2
    
3.
Alencar JE, Neves J, Dietze R. Leishmaniose visceral (calazar). In: Veronesi R, Focaccia R, Dietze R, editors. Tratado De Infectologia. 9th ed. Tratado de Infectologia. Sa˜o Paulo: Atheneu; 1997.  Back to cited text no. 3
    
4.
Annajar B. Collaborative Research Opportunities in North Africa and the Middle East Conference. Research Abstract; 22-25 June, 2009.  Back to cited text no. 4
    
5.
Elhosk MA, Shaibi T, Annajar BB, Scalini A, Maroli M. A preliminary investigation on Phlebotomus Longicusps Nitzulescu the suscpected vector of visceral leishmaniasis in the North Easthern region of Libya. Int J Adv Res 2014;2:411.  Back to cited text no. 5
    
6.
Meinecke CK, Schottelius J, Oskam L, Fleischer B. Congenital transmission of visceral leishmaniasis (Kala Azar) from an asymptomatic mother to her child. Pediatrics 1999;104:e65.  Back to cited text no. 6
    
7.
Boehme CC, Hain U, Novosel A, Eichenlaub S, Fleischmann E, Löscher T. Congenital visceral leishmaniasis. Emerg Infect Dis 2006;12:359-60.  Back to cited text no. 7
    
8.
Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother 2015;16:237-52.  Back to cited text no. 8
    
9.
Figueiro-Filho EA, Duarte G, El-Beitune P, Quintana SM, Maia TL. Visceral leishmaniasis (kala-azar) and pregnancy. Infect Dis Obstet Gynecol 2004;12:31-40.  Back to cited text no. 9
    
10.
Panagopoulos P, Mitsopoulos V, Papadopoulos A, Theodorou S, Christodoulaki C, Aloupogiannis K, et al. Visceral leishmaniasis during pregnancy: A rare case report from Greece. PLoS Negl Trop Dis 2017;11:e0005134.  Back to cited text no. 10
    
11.
Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S. Orally effective drugs for kala-azar (visceral leishmaniasis): Focus on miltefosine and sitamaquine. J Assoc Physicians India 2003;51:686-90.  Back to cited text no. 11
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Case Report
Discussion
Conclusions
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed60    
    Printed0    
    Emailed0    
    PDF Downloaded11    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]